01/18/22 9:25 AMNasdaq : BFRI, BFRIW high shortlow floatBiofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for 2022 and BeyondBiofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today issued the following letter from CEO Erica Monaco and Executive Chairman of the Board HermannRHEA-AIvery positive
01/13/22 8:45 AMNasdaq : BFRI, BFRIW high shortlow floatBiofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter and full year ended December 31, 2021.RHEA-AIneutral
01/10/22 8:45 AMNasdaq : BFRI, BFRIW high shortlow floatBiofrontera Inc. Announces Participation in Two Dermatology Conferences in JanuaryBiofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that it plans to participate in the following two dermatology conferences in January:RHEA-AIvery positive
12/30/21 8:45 AMNasdaq : BFRI, BFRIW high shortlow floatBiofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercisesBiofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the exercise of outstanding warrants the majority ownership of Biofrontera AG was diluted belowRHEA-AIneutral
12/13/21 9:09 AMNasdaq : BFRI, BFRIW clinical trialhigh shortlow floatBiofrontera Inc. Announces Enrollment of First Subject in Phase 2b Clinical Trial Evaluating Ameluz® + BF-RhodoLED® in Moderate-to-Severe AcneBiofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the first subject has been enrolled in the Phase 2b study performed by Biofrontera Bioscience GmbHRHEA-AIneutral
12/08/21 9:32 AMNasdaq : BFRI, BFRIW high shortlow floatBiofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lampBiofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance forRHEA-AIvery positive
12/06/21 9:00 AMNasdaq : BFRI, BFRIW clinical trialhigh shortlow floatBiofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the first subject has been enrolled in a Phase 1 study to evaluate the safety and tolerability ofRHEA-AIneutral
12/02/21 9:15 AMNasdaq : BFRI, BFRIW high shortlow floatBiofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination ProtocolBiofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S.RHEA-AIpositive
12/01/21 7:05 PMNasdaq : BFRI, BFRIW high shortlow floatBiofrontera Inc. Announces Closing of $15 Million Private PlacementBiofrontera Inc. (Nasdaq: BFRI; BFRIW) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the closing of a private placement with a single institutional investor for theRHEA-AIneutral
11/30/21 9:20 AMNasdaq : BFRI, BFRIW earningshigh shortlow floatBiofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business UpdateBiofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today financial results for the three and nine months endedRHEA-AIneutral
